Montanide Isa 51
PD-L1 Positive
Roswell Park Cancer InstitutePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
12 Active assets in the PD-L1 Positive cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Gilead Sciences | Phase 3 | B |
Pembrolizumab Gilead Sciences | Phase 3 | B |
Epirubicin Gilead Sciences | Phase 3 | B |
Carboplatin Gilead Sciences | Phase 3 | B |
Limertinib Shanghai Chest Hospital | Phase 2 | CCC |
View all 12 →
Same molecule, other indications
Montanide Isa 51 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →